Literature DB >> 15003515

Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5.

Shinichiro Takahashi1, Hideo Harigae, Mitsuo Kaku, Takeshi Sasaki, Jonathan D Licht.   

Abstract

Flt3 is a type III RTK and approximately 30% of AML patients harbor an internal tandem duplication (ITD) of the juxtamembrane region or a point mutation of the Flt3 protein leading to the constitutive activation of downstream signaling pathways and aberrant cell growth. The cyclin-dependent kinase inhibitor p21 inhibits cell growth when expressed at high levels and induces cell growth when expressed at lower levels. In this study, we have addressed the role of Flt3-ITD in the regulation of p21. Co-transfection of p21 promoter-luciferase constructs with Flt3-ITD plasmid into K562 and BaF3 cells results in the induction of p21 promoter activity and a -692/-684 STAT site is important for the induction. STAT5a binds specifically to this element and Flt3-ITD enhances the protein binding to this site. Overexpression of Flt3-ITD led to the induction of endogenous p21 expression in various cells. These results may implicate p21 in Flt3-ITD induced leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003515     DOI: 10.1016/j.bbrc.2004.02.018

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Authors:  Xiaoyang Li; Yuqi Jiang; Yuri K Peterson; Tongqiang Xu; Richard A Himes; Xin Luo; Guilin Yin; Elizabeth S Inks; Nathan Dolloff; Stephanie Halene; Sherine S L Chan; C James Chou
Journal:  J Med Chem       Date:  2020-05-06       Impact factor: 7.446

Review 2.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 3.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

4.  Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.

Authors:  Guiyun Song; Benigno C Valdez; Yang Li; Yan Liu; Richard E Champlin; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2014-08-09       Impact factor: 5.742

5.  Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.

Authors:  Shinichiro Takahashi; Hideo Harigae; Hisayuki Yokoyama; Izumi Ishikawa; Shouri Abe; Masue Imaizumi; Takeshi Sasaki; Mitsuo Kaku
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

6.  Internal tandem duplication and tyrosine kinase domain mutations in FLT3 alter the response to daunorubicin in Ba/F3 cells.

Authors:  Shinichiro Takahashi; Kumi Shirahama
Journal:  Biomed Rep       Date:  2015-11-09

7.  Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5.

Authors:  Fulu Liu; Ghada Kunter; Maxwell M Krem; William C Eades; Jennifer A Cain; Michael H Tomasson; Lothar Hennighausen; Daniel C Link
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

8.  The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.

Authors:  Luke F Peterson; Ming Yan; Dong-Er Zhang
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

Review 9.  Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.

Authors:  Shinichiro Takahashi
Journal:  J Hematol Oncol       Date:  2011-04-01       Impact factor: 17.388

Review 10.  An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment.

Authors:  Tiziana Grafone; Michela Palmisano; Chiara Nicci; Sergio Storti
Journal:  Oncol Rev       Date:  2012-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.